Answers are grounded in this paper and cite their sources.
Mitochondrial dysfunction is increasingly linked to breast cancer progression. Among emerging “mitoepigenetic” changes, mitochondrial DNA (mtDNA) methylation is gaining attention as a possible biomarker and regulator of tumor biology, with roles in metabolic reprogramming and oxidative stress responses. This review summarizes current evidence for mtDNA methylation in breast cancer, emphasizing molecular mechanisms, biological significance, and key methodological challenges. We discuss how mtDNA methylation is controlled by mtDNA methyltransferases (bDNMT1, DNMT3A, DNMT3B) and by demethylation pathways involving TET enzymes and AlkB family proteins. Evidence suggests that aberrant mtDNA methylation can influence mitochondrial gene expression, oxidative phosphorylation, reactive oxygen species (ROS) production, immune responses, and metastatic potential. We also review reported associations between mtDNA methylation patterns, mtDNA variants, breast cancer susceptibility, and prognosis. A major focus is the evaluation of methods to measure mtDNA methylation, including bisulfite sequencing, pyrosequencing, methylated DNA immunoprecipitation, and newer long-read platforms such as nanopore and PacBio. Finally, we highlight research gaps and future directions to improve the reliability and interpretation of mitoepigenetic studies. Understanding mtDNA methylation may enable new biomarker discovery and more personalized therapeutic strategies targeting mitochondrial dysfunction in cancer.
No takes yet. Share an insight, caveat, or question.
Cotino‐Nájera et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: